Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

Blood (2023) 142 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2023-186762

Published: 2023

Journal Articles

The Transcriptional Impact of 5q Deletion in MDS at Single Cell Resolution

Blood (2023) 142 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2023-186173

Published: 2023

Journal Articles

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Antonieta Molero Yordi, Soraya Peralta Garzón, Laura Gallur, Barbara Tazon, Daniel Medina, Victor Navarro Garces, Maria Julia Montoro, Silvia Saumell, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso Pierola, Felipe Prosper, Maria Diez-Campelo, Olga Salamero, Ana Pérez González, Sara Garrido Paniagua, David Valcarcel

Blood (2023) 142 (Supplement 1): 6457.

https://doi.org/10.1182/blood-2023-185616

Published: 2023

Journal Articles

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Blood (2023) 142 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2023-189503

Published: 2023

Journal Articles

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Sandra Novoa Jáuregui, Laura Palomo, Ana Pérez, Bárbara Tazón, Maria Julia Montoro, Adoracion Blanco, Silvia Saumell, Laura Gallur, Eugenia Rivero, Sara Garrido, Marc Bosch Schips, Sofia Laura Muzio, Margarita Ortega, Antonieta Molero Yordi, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 6966–6967.

https://doi.org/10.1182/blood-2022-168705

Published: 2022

Journal Articles

Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 5852–5854.

https://doi.org/10.1182/blood-2022-166921

Published: 2022

Journal Articles

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Soraya Peralta, Laura Gallur, Bárbara Tazón, Víctor Navarro Garcés, Silvia Saumell, Maria Julia Montoro, Olga Salamero, Ana Pérez González, Sara Garrido, Maria Sola, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso-Pierola, Lídia Altimiras, Maria Diez-Campelo, Felipe Prosper, David Valcárcel

Blood (2022) 140 (Supplement 1): 4024–4025.

https://doi.org/10.1182/blood-2022-163188

Published: 2022

Journal Articles

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose A. Perez-Simon, Rosa Coll, Montserrat Arnan, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Mabel Arevalo, Sonia Gutierrez, Carlos Buesa, Douglas V Faller, Francesc Bosch, Pau Montesinos

Blood (2022) 140 (Supplement 1): 1711–1713.

https://doi.org/10.1182/blood-2022-168945

Published: 2022

Journal Articles

The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy

Amir T. Fathi, Mabel Arevalo, Sonia Gutierrez, Antonieta Molero, Natalia Sacilotto, Ana Limon, Douglas V Faller

Blood (2022) 140 (Supplement 1): 11755–11756.

https://doi.org/10.1182/blood-2022-160427

Published: 2022

Journal Articles

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, Silvia Saumell, Mayda Navarrete, Margarita Ortega, Bárbara Tazón, Antonieta Molero, Olga Salamero, Sandra Novoa Jáuregui, Sofia Laura Muzio, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 12308–12310.

https://doi.org/10.1182/blood-2022-157434

Published: 2022

Journal Articles

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Bárbara Tazón, Laura Gallur, Silvia Saumell, Tamara Jimenez, Teresa Ezponda, Maria Julia Montoro, Félix López Cadenas, Lídia Altimiras, Carla Sánchez Ruiz, Ana Alfonso, Olga Salamero, Ana Pérez, Soraya Peralta, Maria Diez-Campelo, Felipe Prosper, Francesc Bosch, David Valcarcel

Blood (2021) 138 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2021-150104

Published: 2021

Journal Articles

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

María Diez-Campelo, Luis E. Benlloch, Emma Sasse, David Wormser, Leyla Hernandez Donoso, Silvia Colicino, Teresa Bernal, Antonieta Molero Yordi, Mar Tormo, Montserrat Arnan Sangerman, Guillermo Sanz, Marina Díaz-Beyá, María Teresa Cedena Romero, Andres Jerez, Brayan Merchán, David Valcárcel

Blood (2021) 138 (Supplement 1): 2605.

https://doi.org/10.1182/blood-2021-146019

Published: 2021

Journal Articles

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose Pérez-Simón, Rosa Coll, Montserrat Arnan Sangerman, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Sonia Gutierrez, Carlos Buesa, Francesc Bosch, Pau Montesinos

Blood (2021) 138 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2021-152183

Published: 2021

Journal Articles

Single-Cell Transcriptomics Study of Human Hematopoietic Progenitors Reveals Alterations Associated with Aging and Myeloid Malignancies

Blood (2021) 138 (Supplement 1): 1082.

https://doi.org/10.1182/blood-2021-153550

Published: 2021

Journal Articles

Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial)

Olga Salamero, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Antonieta Molero, MD, Evelyn Acuña, MD, Ana Perez, MD, Isabel Cano, MD, Rebeca Rodríguez-Veiga, MD, Sonia Gutierrez, Roger Bullock, MD, Carlos Buesa, PhD, Francesc Bosch, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-134310

Published: 2020

Journal Articles

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136197

Published: 2020

Journal Articles

Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndromes

Maria Julia Montoro, MD, Ana Perez, MD, Silvia Saumell, MD PhD, Maida Navarrete, MD, Gael Roue, PhD, Moraima Jimenez, MD, Margarita Ortega, PhD, Bárbara Tazón, PhD, Antonieta Molero, MD, Olga Salamero, MD, Francesc Bosch, MD PhD, David Valcarcel, MD

Blood (2019) 134 (Supplement_1): 3011.

https://doi.org/10.1182/blood-2019-123185

Published: 2019

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation

Blood (2019) 134 (Supplement_1): 3764.

https://doi.org/10.1182/blood-2019-122686

Published: 2019

Journal Articles

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

Julia Montoro, Helena Pomares, Brayan Merchan, Antonieta Molero, Silvia Saumell, Esther Alonso, Mónica Fernández, Laura Gallur, Javier Grau, Olga Salamero, Adoración Blanco, Anna Varela, Elisa Roldán, Anna Sureda, Francesc Bosch, Montserrat Arnan Sangerman, David Valcarcel

Blood (2017) 130 (Supplement 1): 5306.

https://doi.org/10.1182/blood.V130.Suppl_1.5306.5306

Published: 2017

NARROW

Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

The Transcriptional Impact of 5q Deletion in MDS at Single Cell Resolution

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Single-Cell Transcriptomics Study of Human Hematopoietic Progenitors Reveals Alterations Associated with Aging and Myeloid Malignancies

Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial)

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndromes

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only